The FTSE 100 index lost just 0.29 points at 8,822.91. The FTSE 250 ended down 145.24 points, 0.7%, at 21,557.34, and the AIM All-Share closed down 2.76 points, 0.4%, at 773.49.

Back in February 2024, Synergia and Selan, a Gandhinagar, India-based mining firm, executed a farm-out agreement to set up a joint venture at Cambay.

(Alliance News) - AFC Energy PLC on Friday said it has agreed to form a 50:50 joint venture with Industrial Chemicals Group Ltd to produce hydrogen from ammonia using its proprietary ammonia cracking ...

Both based in London, Pri0r1ty provides software-as-a-service focused on AI, while Halfspace uses data capture for sports and entertainment advertising. The firms plan to share cross-selling ...

Battery electric car purchases climbed 39% to 47,354 units in June from 34,034 a year prior, lifting EV market share to just under 25%. SMMT noted that this is still below UK government-mandated ...

(Sharecast News) - London stocks were still weaker by midday on Friday as Donald Trump's 9 July tariff deadline loomed, with trade expected to remain quiet as US markets will be closed for ...

The pound was quoted down at USD1.3650 at midday on Friday in London, compared to USD1.3654 at the equities close on Thursday. The euro stood higher at USD1.778, against USD1.1762. Against the yen, ...

Versarien PLC, up 23% at 0.016 pence, 12-month range 0.013p-0.14p. The Gloucestershire, England-based advanced materials engineering group extends its existing manufacturing licence deal, and know-how ...

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

(Alliance News) - The UK high street suffered a disappointing June with consumers being "incredibly cautious" amid rising job losses and volatile geopolitics, latest figures show.

(Alliance News) - An estimated GBP40.7 billion in savings collectively held by "self-made" people who have risen up the income rankings could be unlocked and invested towards fuelling UK economic ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.